Mechanistic evaluation of glucose-lowering strategies in patients with heart failure - MEASURE-HF

Study identifier:D1680C00016

ClinicalTrials.gov identifier:NCT02917031

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients with Type 2 Diabetes Mellitus and Heart Failure

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 4

Healthy volunteers

No

Study drug

Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin, Placebo to match sitagliptin

Sex

All

Actual enrollment

348

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 10 Jan 2017
Primary Completion Date: 23 Aug 2019
Study Completion Date: 23 Aug 2019

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria